[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Other Articles
June 5, 1937


JAMA. 1937;108(23):1973-1974. doi:10.1001/jama.1937.02780230033012

Since the advent of ephedrine in modern therapy, a number of similar vasoconstrictors have been proposed primarily for their use in rhinology. Benzedrine, one of this group, has been accepted by the Council on Pharmacy and Chemistry.1 Benzedrine, as well as its carbonate, differs from other vasoconstrictors which are used for this purpose in being volatile and effective by inhalation.2 During the past year a nonvolatile salt of benzedrine—the sulfate—has been introduced and has been extensively exploited as a stimulant for the brain and a producer of sleeplessness. This promotion followed exaggeration in newspaper accounts of the results of experiments made with the drug in psychologic investigations.

The inhalation of benzedrine for its vasoconstrictor action occasionally resulted in sleeplessness after overdosage. This action led to its use3 and later to the use of the sulfate4 orally for the treatment of narcolepsy and postencephalitic parkinsonism. The sulfate